Publication Name	World Journal of Clinical Cases
Manuscript ID	63794
Country	Portugal

Received	2021-02-08 11:29
Peer-Review Started	2021-02-08 11:33
To Make the First Decision
Return for Revision	2021-04-25 04:46
Revised	2021-05-04 15:45
Second Decision	2021-05-08 06:28
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2021-05-08 08:49
Articles in Press	2021-05-08 08:49
Publication Fee Transferred
Edit the Manuscript by Language Editor	2021-05-13 19:27
Typeset the Manuscript	2021-05-29 03:52
Publish the Manuscript Online	2021-06-11 09:22

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Case Report
Article Title	Long-term response to avelumab and management of oligoprogression in Merkel cell carcinoma: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Inês Leão, Joana Marinho and Telma Costa
ORCID	Author(s) ORCID Number Inês Leão http://orcid.org/0000-0002-6586-4980 Joana Marinho http://orcid.org/0000-0003-3665-4666 Telma Costa http://orcid.org/0000-0002-9625-1124
Funding Agency and Grant Number
Corresponding Author	Telma Costa, MD, Doctor, Doctor, Department of Oncology, Centro Hospitalar Vila Nova de Gaia/Espinho, Rua Conceição Fernandes, Vila Nova de Gaia 4434-502, Portugal. telma.r.c.costa@gmail.com
Key Words	Merkel cell carcinoma; Unresectable tumor; Avelumab; Oligoprogression; Surgery; Chemotherapy; Case report
Core Tip	This report highlights the efficacy and long-term response of avelumab, on the management of a chemotherapy resistant advanced Merkel cell carcinoma (MCC). It shows also a successful approach to oligoprogression with local radical treatment, surgery and radiotherapy, while maintaining systemic therapy with avelumab. The results support the effectiveness of this strategy for the management of unresectable MCC.
Publish Date	2021-06-11 09:22
Citation	Leão I, Marinho J, Costa T. Long-term response to avelumab and management of oligoprogression in Merkel cell carcinoma: A case report. World J Clin Cases 2021; 9(18): 4829-4836
URL	https://www.wjgnet.com/2307-8960/full/v9/i18/4829.htm
DOI	https://dx.doi.org/10.12998/wjcc.v9.i18.4829

Full Article (PDF)	WJCC-9-4829.pdf
Full Article (Word)	WJCC-9-4829.docx
CARE Checklist–2016	63794-CARE-Checklist–2016-revision.pdf
Manuscript File	63794-Review-FilipodiaCL.docx
Answering Reviewers	63794-Answering reviewers.pdf
Audio Core Tip	63794-Audio core tip.ogg
Conflict-of-Interest Disclosure Form	63794-Conflict-of-interest statement.pdf
Copyright License Agreement	63794-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s)	63794-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	63794-Language certificate.pdf
Peer-review Report	63794-Peer-review(s).pdf
Scientific Misconduct Check	63794-Bing-Fan JR-2.png
Scientific Misconduct Check	63794-Bing-Ma YJ-1.jpg
Scientific Misconduct Check	63794-Scientific misconduct check.pdf
Scientific Editor Work List	63794-Scientific editor work list.pdf
CrossCheck Report	63794-CrossCheck report.pdf
CrossCheck Report	63794-CrossCheck.png